1 Title Page

2

3 Title:

4 Identification of noninvasive and disease-specific biomarkers in hereditary5 angioedema using urinary proteomics

6

Jianqiang Wu^{a#}, Xiaoyue Tang^{a#}, Xue Wang^{b#}, Peng Liu^{a#}, Nan Zhou^b, Zejian Zhang
 ^a, Yang Cao^b, Shuyang Zhang^{c*}, Yuxiang Zhi^{b*}

9

^a Medical Research Center, State Key Laboratory of Complex Severe and Rare
 Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical
 Sciences & Peking Union Medical College, Beijing 100730, China;

^b Department of Allergy & Clinical Immunology, National Clinical Research Center

for Immunologic Diseases, State Key Laboratory of Complex Severe and RareDiseases, Peking Union Medical College Hospital, Chinese Academy of Medical

16 Sciences & Peking Union Medical College, Beijing 100730, China;

^c State Key Laboratory of Complex Severe and Rare Diseases, Department of
 Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical

19 Sciences & Peking Union Medical College, Beijing 100730, China.

20

21 *Correspondence

Yuxiang Zhi, Department of Allergy & Clinical Immunology, Peking Union Medical
College Hospital, No. 1 Shuaifuyuan, Beijing 100730, China. E-mail:

- 24 yuxiang_zhi@126.com;
- 25

26 Shuyang Zhang, State Key Laboratory of Complex Severe and Rare Diseases, Peking

27 Union Medical College Hospital, E-mail: shuyangzhang103@nrdrs.org

28

29 Abstract

Background: Hereditary angioedema (HAE) is a rare and potentially life-threatening

disease. Noninvasive and disease-specific biomarkers are needed for the earlydiagnosis and clinical management of HAE.

Objective: We sought to apply untargeted proteomics profiling and targeted
 proteomics validation to identify pathogenic mechanisms and candidate biomarkers of
 HAE.

Methods: Data-independent acquisition (DIA)-based proteomics profiling was performed in urine samples of HAE patients and healthy controls. Bioinformatics analysis was used for functional annotation and pathway enrichment of differentially expressed proteins. Furthermore, promising biomarker candidates were validated in

40 another independent clinical cohort using parallel reaction monitoring (PRM) targeted

41 proteomics quantification.

42 **Results:** Different urinary proteomics profiles were identified among type 1 HAE,

43 type 2 HAE and healthy controls. A total of 401 differentially expressed proteins were

44 identified between type 1 HAE and healthy controls. Bioinformatics analysis showed

45 that several biological processes and pathways were significantly enriched in HAE, including complement and coagulation cascades, cell adhesion molecules, immune 46 47 response, proteolysis, and bradykinin catabolic process. Moreover, a promising 48 biomarker panel (C1-INH, KNG1 and EGF) were validated in another independent 49 clinical cohort. The area under the curve (AUC) value of this biomarker panel reached 50 0.910 for HAE diagnosis (sensitivity: 91.7, specificity: 88.9, P < 0.001).

51 Conclusions: This study describes the first application of a DIA-PRM workflow to 52 identify noninvasive and disease-specific biomarkers in HAE patients. These findings 53 will contribute to the pathogenesis research and biomarker discovery of HAE.

54

55 **Key Messages**

- 56 1. Different urinary proteomics profiles were identified among type 1 HAE, type 2 57 HAE and healthy controls.
- 58 2. Several biological processes and pathways were significantly enriched in HAE, 59 including complement and coagulation cascades, cell adhesion molecules, 60 immune response, proteolysis, and bradykinin catabolic process.
- 3. A urinary biomarker panel (C1-INH, KNG1, and EGF) could be a promising 61 62 noninvasive diagnostic tool for HAE.
- 63
- Key words: hereditary angioedema; pathogenesis; biomarkers; proteomics; urine. 64
- 65

Abbreviations Used: 66

67 HAE, hereditary angioedema; HC, heathy control; LC-MS/MS, liquid 68 chromatography coupled with tandem mass spectrometry; DIA, data-independent 69 acquisition; PRM, parallel reaction monitoring; DEP, differentially expressed protein; 70 C1-INH or SERPING1, Protease C1 inhibitor; KNG1, Kininogen-1; EGF, 71 Pro-epidermal growth factor; CLU, Clusterin; ROC, receiver operator characteristics; 72 AUC, area under the curve.

73

74 1. Introduction

75 Hereditary angioedema (HAE) is clinically characterized by recurrent attacks of 76 subcutaneous and submucosal swelling, which involves the face, extremities, trunk, genitalia, upper airways, and/or gastrointestinal tract¹. Classic HAE is caused by 77 mutation of the SERPING1 gene, which causes plasma protease C1 inhibitor (C1-INH) 78 deficiency². HAE with C1-INH deficiency can be subdivided into type 1 (decreased 79 plasma levels of C1-INH) and type 2 (normal levels but dysfunction of C1-INH). 80 Type 1 HAE accounts for the majority of HAE cases in China, and the percentage of 81 type 2 HAE cases in China is < 5%. Other types of HAE due to defects in coagulation 82 factor XII, plasminogen, or angiopoietin-1 have not been reported in China³. 83

HAE is a rare disease with an estimated prevalence of 1/50,000 and is often not 84 recognized ⁴. As abdominal symptoms are common and important clinical features, 85 HAE is easily misdiagnosed, which can lead to unnecessary surgical procedures 5,6 . 86 87 Furthermore, all HAE patients are at risk of a laryngeal attack, and more than 50% 88 have laryngeal attacks during their lifetime. Laryngeal edema-induced asphyxiation

89 without timely treatment is the main cause of death in HAE patients, and the mortality 90 rate ranges between 11% and 40% ⁷⁻⁹. However, previous studies have reported that 91 the interval between the onset of symptoms and final diagnosis of HAE remains 8-13 92 years ^{4,10,11}. Long diagnostic delay and inappropriate treatment will aggravate the 93 humanistic and economic burden for HAE patients ¹². Therefore, early diagnosis and 94 disease evaluation are essential to improve the quality of life and clinical management 95 of HAE patients.

96 Biomarkers are measurable changes associated with physiological or pathophysiological conditions ^{13,14}. Without homeostatic control, urine accumulates 97 systematic changes in the body and has the potential to reflect small and early 98 pathological conditions ¹⁴. Moreover, urine can be collected noninvasively and in 99 large volume. Thus, urine is an attractive sample source for biomarker research. 100 Proteomics is a powerful tool in biomarker discovery, exploration of pathogenesis, 101 and drug target identification ¹⁵. With the rapid development of mass spectrometry 102 (MS) techniques, urinary proteomics has become a promising field in biomarker 103 discovery ¹⁶. The urinary proteome is mainly composed of plasma proteins that pass 104 the glomerular barrier and proteins shed by cells within the urogenital system. Thus, 105 106 urinary proteomics could reflect both systemic and local conditions of the body. Currently, in addition to its application in urological diseases ¹⁷, urinary proteomics 107 has also been applied in cardiovascular diseases ¹⁸, brain diseases ¹⁹ and other diseases 108 ²⁰⁻²². Although urinary biomarkers have been investigated in many diseases, no urine 109 biomarkers are currently available for the diagnosis, disease monitoring and 110 therapeutic efficacy evaluation of HAE²³. Advances in high-throughput proteomics 111 technology may facilitate the discovery of promising noninvasive urine biomarkers of 112 113 HAE.

114 In this study, the data-independent acquisition (DIA)-based proteomics technique 115 was applied to explore the urinary protein profiling of HAE patients. Bioinformatics 116 analysis was performed to annotate the biofunctions and pathways of the differentially 117 expressed proteins (DEPs). Then, several promising biomarkers were further 118 validated in another independent clinical cohort using parallel reaction monitoring 119 (PRM)-based targeted proteomics. This study will provide a novel noninvasive 120 method for HAE diagnosis and will improve our understanding of the pathogenesis of 121 HAE.

123 **2. Methods**

122

124 **2.1 Patients and sample collection**

In the biomarker discovery phase, 20 adult HAE patients and 29 healthy controls 125 126 (HCs) were recruited from Peking Union Medical College Hospital (PUMCH) during 127 2020. Among these patients, 15 had type 1 HAE, and 5 had type 2 HAE. In the 128 biomarker validation phase, 24 other type 1 HAE patients and 18 HCs were recruited 129 from PUMCH during 2021. This study was conducted in accordance with the 130 Declaration of Helsinki (as revised in 2013). All HAE patients and HCs provided 131 written informed consent, and the Ethics Committee of PUMCH approved this study 132 (No. HS-2402).

Midstream first morning urine was collected from these subjects. Routine urine test results were normal in all subjects. After collection, the urine samples were centrifuged at $3,000 \times g$ for 20 min at 4 °C to remove the cell debris, and the supernatants were stored at -80 °C for further proteomics analysis.

137 2.2 Sample preparation

Samples were prepared using a filter-aided sample preparation method as previously 138 described ²⁴. Briefly, samples were reduced with 20 mM dithiothreitol at 100 °C for 139 10 min and alkylated with 50 mM iodoacetamide at room temperature for 30 min in 140 141 the dark. Then, urinary proteins were extracted from the samples by acetone 142 precipitation, and the pellets were resuspended with 20 mM Tris buffer. Then, $100 \mu g$ 143 of protein was loaded onto 30-kD filter devices (Pall, Port Washington, NY, USA) and 144 centrifuged at $14,000 \times g$ at 18 °C. After washing three times with 20 mM Tris buffer, 145 the samples were digested with trypsin at 37 °C overnight. Finally, 2 µg of each 146 peptide sample was used for the subsequent $LC \square MS/MS$ analysis.

147 2.3 DIA quantitative proteomic analysis

148 LC MS/MS analysis was performed by an Orbitrap QE HF mass spectrometer coupled with an EASY-nLC 1200 UHPLC system (Thermo Fisher Scientific, 149 150 Waltham, MA, USA). Digested peptides were loaded onto a trap column (75 μ m \times 2 151 cm, 3 μ m, C18, 100 A°). The peptides were separated on an analytical column (75 μ m 152 \times 500 mm, Kyoto Monotech, Kyoto, Japan). The elution was set to 5–30% buffer B 153 (0.1% formic acid in 99.9% acetonitrile; flow rate of 0.3 µl/min) for 60 min. Moreover, an iRT kit (Biognosys, Schlieren, Switzerland) was added to all samples to 154 make retention time alignments among samples ²⁵. The MS was set in DIA mode, and 155 the parameters were set as follows: the full scan was performed with a resolution of 156 157 120,000 and in the range of 350–1,500 m/z; the cycle time was 3 s; the automatic gain 158 control (AGC) was 3e6, and the injection time was under 100 ms; precursors were 159 selected by charge state screening with a +2 to +6 charge state; and the dynamic 160 exclusion duration was 10 s. During the DIA analysis, a mixed sample was inserted 161 after every ten samples for quality control (QC).

162 2.4 PRM proteomics validation

163 First, pooled peptide samples were subjected to LC MS/MS analysis with six 164 technical replicates. Skyline software was used to build the spectrum library and 165 screen peptides for PRM analysis. For each targeted protein, two to five peptides were 166 selected using the following criteria: identified with q value < 1%, completely 167 digested by trypsin, 8-18 amino acid residues, exclusion of the first 25 \neq N-terminal 168 amino acids, and carbamidomethylation of cysteine as the fixed modification. Only 169 unique peptides of each protein were used for further PRM quantitation. The retention 170 time (RT) segment was set to $\pm 2 \square$ min for each targeted peptide, with its expected RT 171 in the center based on the pooled sample analysis.

To ensure data quality, a mixed sample was used as the quality control after every samples to determine the stability of the instrument signal. To further ensure data quality, an iRT standard was added to each sample, and the stability of the chromatographic retention time was evaluated during the analysis. To reduce any system bias, different groups of samples were analyzed in a random order.

177 2.5 MS data processing and analysis

All raw MS data in the DIA experiment were imported into Spectronaut software 178 179 (Biognosys AG, Switzerland) to generate the spectra library. The data were searched 180 against the UniProt human database appended with the iRT fusion protein sequence. 181 The parent ion tolerance was set at 10 ppm, and the fragment ion mass tolerance was 182 set to 0.05 Da. A maximum of two missed cleavage sites in the trypsin digestion was 183 allowed. Carbamidomethylation of cysteines was set as a fixed modification, and the 184 oxidation of methionine was considered a variable modification. Then, the DIA raw 185 files were searched against the self-built spectra library using Spectronaut Pulsar X. 186 The optimal XIC extraction window was determined according to the iRT calibration 187 strategy. The cross-run normalization was set to the local normalization based on the 188 local regression. Protein inference was performed using the implemented IDPicker algorithm ²⁶. The Q value was set to 0.01 for data filtering. The sum peak areas of the 189 respective fragment ions in MS₂ were used to quantify peptide intensities. 190

191 For the PRM validation, the MS data were processed with Skyline software. The 192 transition settings in Skyline were as follows: precursor charges, +2 to +5; ion types, 193 b, y, and p; the product ions from ion 3 to last ion -1; ion match tolerance, $0.02 \square m/z$; 194 the six most intense product ions were picked; and the variable "min dotp" was set to 195 0.7. The correct peaks were selected manually, and all of the peptide results were 196 exported. Total ion current (TIC) chromatograms were obtained for each sample in the 197 range of a +2 to +5 charge using Progenesis QI for Proteomics software. The mass 198 spectra data for each peptide were normalized with the TIC chromatogram of its 199 associated sample to correct for sample size and mass signal intensity errors. The 200 results for each peptide were quantitatively analyzed, and the identified differential 201 proteins were screened and compared with the DIA results.

202 2.6 Bioinformatics and statistical analysis

Functional annotation of differentially expressed proteins (DEPs) was performed 203 using DAVID database²⁷. The biological process, cellular component and molecular 204 205 function of DEPs were enriched. For Ingenuity Pathway Analysis (IPA), the SwissProt 206 accession numbers were uploaded to IPA software (Ingenuity Systems, CA, United States). The biofunction and canonical pathway of DEPs were enriched. Pattern 207 208 recognition analysis (principal component analysis, PCA; orthogonal partial least 209 squares discriminant analysis, OPLS-DA) was conducted by SIMCA software 210 (version 15.0, Umetrics, Sweden). The statistical analysis was performed with 211 GraphPad Prism (version 8.0.2, GraphPad Software Inc., San Diego, California, USA). 212 Receiver operating characteristic (ROC) analysis was performed with the "Biomarker 213 discovery" module on the MetaAnalyst 5.0 website (https://www.metaboanalyst.ca/).

214

215 3. Results

216 **3.1 Clinical characteristics of subjects and study design**

A total of 44 HAE patients and 47 healthy controls were recruited in this study. In the
discovery phase, 20 newly diagnosed HAE patients (type 1: 15 patients; type 2: 5
patients) and 29 HCs were included for differential proteome discovery. HAE patients

and healthy controls were matched with age and sex. The average concentration of
plasma C1 inhibitors in type 1 HAE patients was significantly lower than that in type
2 HAE patients and HCs. In the validation stage, another independent clinical cohort
was recruited for biomarker validation, including 24 type 1 HAE patients and 18 HCs.

224 **3.2 DIA-based quantitative proteomics analysis**

In the biomarker discovery stage, urinary samples of 20 HAE patients and 29 HCs were analyzed using the DIA quantitative proteomics method. A quality control sample was used to assess the stability of the results. The correlations of the quantified protein intensities of the QC samples showed satisfactory reproducibility (R^2 -values: > 0.90). A total of 2562 protein groups were identified in the urine samples, and 1716 reliable proteins quantified with at least two unique peptides were used for further analysis.

232 This study compared the urine proteome profiles of HAE patients and HCs. The 233 results showed that there were significantly different urinary proteome profiles among 234 type 1 HAE, type 2 HAE and HCs (Figure 1A). Thus, type 2 HAE may involve 235 different pathophysiological processes compared with type 1 HAE. Interestingly, 236 urinary C1-INH expression was significantly higher in type 2 patients than in type 1 237 HAE patients (ratio = 2.76, p < 0.001). This result was consistent with the higher 238 expression of plasma C1-INH in type 2 HAE than in type 1 HAE. Moreover, the 239 OPLS-DA results showed that type 1 and type 2 HAE had significantly different 240 proteomic expression in urine samples, and these two disease subtypes could be 241 clearly separated from each other in the model (Figure 1B).

242 Because type 1 HAE accounts for more than 95% of all HAE cases in China, the 243 comparison of the urinary proteome between type 1 HAE and HCs was the focus of 244 this study. The PCA and OPLS-DA results showed that type 1 HAE can be 245 distinguished well from HCs based on the urinary protein pattern (Figure 1 C-D). A 246 total of 401 differential urinary proteins were identified (ratio >1.5, p < 0.05). 247 Interestingly, it was found that the abundance of urinary C1IN in type 1 HAE was 248 significantly lower than that of HCs (Ratio=2.79, p<0.0001), suggesting that urinary 249 C1-INH could be a promising noninvasive diagnostic biomarker of type 1 HAE.

250 3.3 Bioinformatics analysis of DEPs between type 1 HAE patients and HCs

251 Functional annotation of the differential proteins between type 1 HAE patients and 252 HCs was performed using the DAVID database. In the biological process category, 253 cell adhesion, immune response, proteolysis, complement activation, blood 254 coagulation, innate immune response in mucosa, and bradykinin catabolic process 255 were significantly enriched (Figure 2A). In the molecular function category, antigen 256 binding, calcium ion binding, collagen binding, integrin binding, cadherin binding, 257 extracellular matrix structural constituent, signaling receptor activity, serine-type 258 endopeptidase inhibitor activity, and protease binding were significantly enriched 259 (Figure 2B).

To identify the major canonical pathways and diseases and biofunctions involved with the differential urine proteins, IPA was used for enrichment analysis. It was 262 demonstrated that IL-15 signaling, B-cell receptor signaling, phagosome maturation, 263 complement system, acute phase response signaling, LXR/RXR activation, 264 coagulation system, and communication between immune cells were significantly 265 enriched (Figure 2C). Furthermore, in the disease and biofunction category, cell 266 movement of blood cells, degranulation of cells, activation of cells, complement 267 activation, angiogenesis, immune-mediated inflammatory disease, peripheral vascular 268 disease, movement of endothelial cells, and hereditary angioedema were significantly enriched during HAE pathogenesis (Figure 2D). Interestingly, eight differential 269 270 proteins identified in our study were annotated in IPA to the disease item "hereditary 271 angioedema", including angiotensin-converting enzyme (ACE), complement C1s 272 subcomponent (C1S), neutrophil elastase (ELANE), coagulation factor XII (F12), 273 kininogen-1 (KNG1), plasminogen (PLG), alpha-1-antitrypsin (SERPINA1), and 274 plasma protease C1 inhibitor (SERPING1 or C1IN). These results indicated that 275 urinary proteomics reflects the pathophysiological changes that occur in HAE.

276 **3.4** Association between the urinary proteome and clinical features

277 These DEPs were then mapped into a coexpression network using STRING and 278 Cytoscape. The most significant cluster of the DEP coexpression network detected by 279 MCC (Cytoscape, CytoHubba) consisted of 10 hub proteins (CLU, C1-INH, CD59, 280 KNG1, C4A, EGF, RAC1, ACE, ANPEP and ENPEP) (Figure 3A). We also analyzed 281 the functions and networks of these hub proteins through GeneMANIA, and the main 282 functions of hub proteins were complement activation and coagulation (Figure 3B). 283 In addition, we selected several hub proteins to construct a biomarker combination, 284 and a biomarker panel consisting of plasma protease C1 inhibitor (SERPING1 or 285 C1-INH), pro-epidermal growth factor (EGF) and kininogen-1 (KNG1) had an ideal 286 diagnostic performance with an AUC of 0.956 (sensitivity: 100%, specificity: 82.8%) 287 (Figure 4A).

288 To demonstrate the clinical utility of our in-depth urinary proteomics analysis, we 289 further analyzed the association between the urinary proteome and disease severity. As previously described ²⁸, a severity scoring system was used to assess the disease 290 severity of HAE, which was mainly based on the onset age, edema location, clinical 291 292 manifestation, and long-term prophylaxis. Our results indicated that the expression 293 levels of two urine proteins (RAC1 and JAM3: junctional adhesion molecule C) were 294 positively correlated with the disease severity score, and the expression levels of six 295 urine proteins (QPCT, ANPEP, B4GALT1, MAN1A1, CLU, and EGF) were 296 negatively correlated with the disease severity score. In particular, CLU was the most 297 significant protein correlated with disease severity (R=-0.758, p=0.001), suggesting 298 that urinary clusterin has the potential to predict the disease severity of HAE (Figure 299 **4B**).

300 3.5 PRM validation of promising biomarkers of HAE

The biomarker panel was further validated in another independent cohort including C1-INH, KNG1, and EGF. To ensure system stability and limit systemic bias during targeted proteomic analysis, QC samples were injected before and after every 10 samples. By performing PCA on both the QC samples and individual urine samples,
the QC samples were closely clustered. The correlation map of QC samples also
showed that the QC samples were highly positively correlated with a Pearson
correlation coefficient above 0.95. These results demonstrated the stability of the MS
platform during proteomics analysis.

According to PRM targeted proteomics quantification, these three proteins showed the same trend as those quantified in the DIA experiment and were significantly decreased in type 1 HAE compared with HCs. Furthermore, the diagnostic performance of this biomarker panel was evaluated using ROC analysis. The results showed that this biomarker panel had good diagnostic performance with an AUC value of 0.910 (sensitivity: 91.7%, specificity: 88.9%) (**Figure 5**).

315

316 4. Discussion

317 In this study, we performed DIA-based urinary proteomics profiling in HAE patients. 318 Several important biological processes and pathways were significantly enriched in 319 the pathogenesis of HAE. Furthermore, some disease-related biomarkers of HAE 320 were identified and further validated in another clinical cohort using PRM-based 321 targeted proteomics quantification. To our knowledge, this is the first application of 322 urinary proteomics analysis in HAE patients, and this study will provide a 323 noninvasive method for HAE diagnosis and improve the understanding of the 324 pathogenesis of HAE.

325 By DIA proteome profiling, it was found that there were significantly different 326 urinary proteome profiles among type 1 HAE patients, type 2 HAE patients and HCs. 327 Thus, although type 1 HAE and type 2 HAE share the deficiency of C1-INH, type 2 328 HAE may involve different pathophysiological processes compared with type 1 HAE. 329 As the sample size of type 2 HAE patients is relatively small, the conclusion needs 330 further confirmation. Interestingly, urinary C1-INH expression was significantly 331 higher in type 2 HAE patients than in type 1 HAE patients (ratio = 2.76, p < 0.001), 332 and urinary C1-INH in type 1 HAE patients was significantly lower than that in HCs (ratio=2.79, p<0.0001). The results suggested that urinary C1-INH is a promising 333 334 noninvasive and disease-specific biomarker for HAE.

335 HAE disease is characterized by recurrent episodes of mucosal edema. Currently, 336 the pathogenesis of HAE is not well understood. Previous studies have revealed that 337 classic HAE is caused by a deficiency of C1-INH, which can regulate proteases in 338 several pathways, including the complement, contact system, coagulation, and 339 fibrinolytic pathways. Moreover, deficiency of C1-INH and activation of the contact 340 system can lead to bradykinin overproduction. Bradykinin is the central mediator of 341 swelling in HAE, and activation of its receptor on vascular endothelial cells leads to vascular instability, hyperpermeability, plasma extravasation, and resultant 342 angioedema^{29,30}. As type 1 HAE accounts for more than 95% of all HAE cases in 343 China¹¹, functional annotation of differential proteins between type 1 HAE patients 344 345 and HCs was the focus of this study. Our results showed that several biologic 346 processes were significantly changed in HAE, such as proteolysis, complement 347 activation, blood coagulation, innate immune response in mucosa, and bradykinin

348 catabolic process. Furthermore, complement activation, angiogenesis, 349 immune-mediated inflammatory disease, peripheral vascular disease, movement of 350 endothelial cells, and hereditary angioedema were significantly enriched in the 351 disease and biofunction category. These bioinformatics results were closely related to 352 the pathophysiology of HAE and will lead to a better understanding of the 353 pathogenesis of HAE. Moreover, eight differential urinary proteins identified in our 354 study were annotated in IPA to the disease item "hereditary angioedema". These 355 results indicated that urinary proteomics reflects the pathophysiological changes that 356 occur in HAE and may serve as a noninvasive biomarker source of HAE.

357 Because the sensitivity and specificity of a single biomarker are often inadequate, 358 the establishment of a biomarker panel is preferred. In this study, we selected several 359 hub proteins in the coexpression analysis to construct a biomarker panel for HAE 360 diagnosis. In the biomarker discovery cohort, a combination of three urinary proteins 361 (C1-INH + KNG1 + EGF) showed good performance for the diagnosis of HAE with 362 an AUC of 0.956. Moreover, this biomarker panel was successfully validated in 363 another independent clinical cohort with an AUC of 0.910, suggesting its good 364 clinical application prospects. C1-INH has serine-type endopeptidase inhibitor 365 activity and plays a crucial role in regulating important physiological pathways, 366 including complement activation, blood coagulation, fibrinolysis, innate immune 367 response and the generation of kinins. Currently, plasma C1-INH is a crucial disease 368 biomarker of HAE in clinical practice. Furthermore, kininogen is an inhibitor of thiol 369 protease. HMW-kininogen plays an important role in blood coagulation, and bradykinin is released from HMW-kininogen as a result of activation of the contact 370 system ³¹. A recent study reported that mutations in the KNG1 gene can cause a novel 371 type of HAE ³². In addition, EGF has rarely been reported in HAE, but EGF can 372 373 regulate endothelial cell migration and proliferation. Thus, EGF may affect vascular 374 endothelial cell organization and plasma extravasation. The role of EGF in the 375 pathogenesis of HAE requires further research. In addition, we observed that urinary 376 CLU was significantly correlated with the disease severity of HAE (R=-0.758, 377 p=0.001). CLU is a regulator of the complement terminal pathway and can sequester 378 terminal complement components C7-C9 to block the assembly of the membrane attack complex (MAC)³³. Thus, urinary CLU is a potential biomarker to predict the 379 380 prognosis of HAE.

381 HAE is a rare and potentially life-threatening disease. This disease is often 382 misdiagnosed for years owing to the general lack of knowledge and its nonspecific 383 manifestations. This condition leads to HAE patients not only suffering from the 384 effects of the disease itself but also from ineffective treatment and needless invasive 385 diagnostic and therapeutic medical procedures. To minimize the suffering and 386 improve quality of life, it is necessary to discover noninvasive and specific 387 biomarkers for HAE. In this study, using DIA- and PRM-based proteomics 388 quantification, we identified several promising biomarkers for HAE. Moreover, 389 significant biological processes and pathways were identified in this study, which 390 would provide references for further investigations on the pathogenesis of HAE. As 391 HAE is a rare disease, the limitation of this study is that it was performed at a single

392 center with a relatively small sample size. In the future, multicenter and prospective

393 clinical validation is needed to verify the clinical application of these biomarkers.

394

395 **5.** Conclusion

To our knowledge, this is the first application of urinary proteomics in HAE patients. Our results showed that the urinary proteome can reflect the pathophysiological changes of HAE and has the potential to serve as a noninvasive biomarker source for the diagnosis and clinical management of HAE. A biomarker panel (C1HN, KNG1, and EGF) showed good performance for the diagnosis of HAE. This study provides a novel noninvasive method for HAE diagnosis and enhances our understanding of the pathogenesis of HAE.

403

404 Acknowledgements

This study was supported by grants from the National Key Research and Development Program of China (No. 2016YFC0901501), the National Natural Science Foundation of China (No. 81472870), the CAMS Innovation Fund for Medical Sciences (CIFMS 2021-1-I2M-003) and Youth Science Fund of Peking Union Medical College Hospital (pumch201912152). The funding organization was not involved in the collection, management, or analysis of the data; preparation or approval of the manuscript; or decision to submit the manuscript for publication.

- 412 **Conflict of interest**
- 413 The authors have no conflicts of interest relevant to this article to disclose.

414 Author Contributions:

JW, YZ and SZ: proposed and designed this study. JW, XT, XW, PL, NZ, ZZ and YC:
collected the samples and performed the experiments. JW, XT, LP and XW: data
analysis. JW and YZ: wrote and revised the manuscript. All authors have accepted
responsibility for the entire content of this manuscript and approved submission.

419

420 **References**

- 421 1. Busse PJ, Christiansen SC. Hereditary Angioedema. N Engl J Med 2020; 382:1136-48.
- 422 2. Xu YY, Gu JQ, Zhi YX. Hereditary angioedema caused by a premature stop codon
 423 mutation in the SERPING1 gene. Clin Transl Allergy 2020; 10:53.
- 424 3. Liu S, Xu Y, Liu Y, Zhi Y. Hereditary angioedema: a Chinese perspective. Eur J Dermatol
 425 2019; 29:14-20.
- 426 4. Zanichelli A, Magerl M, Longhurst H, Fabien V, Maurer M. Hereditary angioedema with
 427 C1 inhibitor deficiency: delay in diagnosis in Europe. Allergy Asthma Clin Immunol 2013;
 428 9:29.
- 429 5. Cao Y, Liu S, Zhi Y. Recurrent and acute abdominal pain as the main clinical
 430 manifestation in patients with hereditary angioedema. Allergy Asthma Proc 2021;
 431 42:131-5.
- 432 6. Hahn J, Hoess A, Friedrich DT, Mayer B, Schauf L, Hoffmann TK, et al. Unnecessary
 433 abdominal interventions in patients with hereditary angioedema. J Dtsch Dermatol Ges
 434 2018; 16:1443-9.
- 435 7. Bork K, Hardt J, Witzke G. Fatal laryngeal attacks and mortality in hereditary

436		angioedema due to C1-INH deficiency. J Allergy Clin Immunol 2012; 130:692-7.
437	8.	Xu YY, Zhi YX, Liu RL, Craig T, Zhang HY. Upper airway edema in 43 patients with
438		hereditary angioedema. Ann Allergy Asthma Immunol 2014; 112:539-44 e1.
439	9.	Bork K, Siedlecki K, Bosch S, Schopf RE, Kreuz W. Asphyxiation by laryngeal edema in
440		patients with hereditary angioedema. Mayo Clin Proc 2000; 75:349-54.
441	10.	Busse PJ, Christiansen SC, Riedl MA, Banerji A, Bernstein JA, Castaldo AJ, et al. US
442		HAEA Medical Advisory Board 2020 Guidelines for the Management of Hereditary
443		Angioedema. J Allergy Clin Immunol Pract 2021; 9:132-50 e3.
444	11.	Xu YY, Jiang Y, Zhi YX, Yin J, Wang LL, Wen LP, et al. Clinical features of hereditary
445		angioedema in Chinese patients: new findings and differences from other populations.
446		Eur J Dermatol 2013; 23:500-4.
447	12.	Liu S, Wang X, Xu Y, Xu Q, Zhi Y. Risk factors for diagnostic delay in Chinese patients
448		with hereditary angioedema. Allergy Asthma Proc 2019; 40:343-9.
449	13.	Gao Y. Urine-an untapped goldmine for biomarker discovery? Sci China Life Sci 2013;
450		56:1145-6.
451	14.	Wu J, Gao Y. Physiological conditions can be reflected in human urine proteome and
452		metabolome. Expert Rev Proteomics 2015; 12:623-36.
453	15.	Wu J, Wang W, Chen Z, Xu F, Zheng Y. Proteomics applications in biomarker discovery
454		and pathogenesis for abdominal aortic aneurysm. Expert Rev Proteomics 2021:1-10.
455	16.	Zhao M, Li M, Yang Y, Guo Z, Sun Y, Shao C, et al. A comprehensive analysis and
456		annotation of human normal urinary proteome. Sci Rep 2017; 7:3024.
457	17.	Tofte N, Lindhardt M, Adamova K, Bakker SJL, Beige J, Beulens JWJ, et al. Early
458		detection of diabetic kidney disease by urinary proteomics and subsequent intervention
459		with spironolactone to delay progression (PRIORITY): a prospective observational study
460		and embedded randomised placebo-controlled trial. Lancet Diabetes Endocrinol 2020;
461		8:301-12.
462	18.	Wang W, Wu J, Liu P, Tang X, Pang H, Xie T, et al. Urinary Proteomics Identifying Novel
463		Biomarkers for the Diagnosis and Phenotyping of Carotid Artery Stenosis. Front Mol
464		Biosci 2021; 8:714706.
465	19.	Wu J, Zhang J, Wei J, Zhao Y, Gao Y. Urinary biomarker discovery in gliomas using mass
466		spectrometry-based clinical proteomics. Chin Neurosurg J 2020; 6:11.
467	20.	Tian W, Zhang N, Jin R, Feng Y, Wang S, Gao S, et al. Immune suppression in the early
468		stage of COVID-19 disease. Nat Commun 2020; 11:5859.
469	21.	Virreira Winter S, Karayel O, Strauss MT, Padmanabhan S, Surface M, Merchant K, et al.
470		Urinary proteome profiling for stratifying patients with familial Parkinson's disease.
471		EMBO Mol Med 2021; 13:e13257.
472	22.	Sun Y, Guo Z, Liu X, Yang L, Jing Z, Cai M, et al. Noninvasive urinary protein signatures
473		associated with colorectal cancer diagnosis and metastasis. Nat Commun 2022; 13:2757.
474	23.	Porebski G, Kwitniewski M, Reshef A. Biomarkers in Hereditary Angioedema. Clin Rev
475		Allergy Immunol 2021; 60:404-15.
476	24.	Wisniewski JR, Zougman A, Nagaraj N, Mann M. Universal sample preparation method
477		for proteome analysis. Nat Methods 2009; 6:359-62.
478	25.	Escher C, Reiter L, MacLean B, Ossola R, Herzog F, Chilton J, et al. Using iRT, a
479		normalized retention time for more targeted measurement of peptides. Proteomics 2012;

480		12:1111-21.		
481	26.	Zhang B, Chambers MC, Tabb DL. Proteomic parsimony through bipartite graph analysis		
482		improves accuracy and transparency. J Proteome Res 2007; 6:3549-57.		
483	27.	Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large		
484		gene lists using DAVID bioinformatics resources. Nat Protoc 2009; 4:44-57.		
485	28.	Bygum A, Fagerberg CR, Ponard D, Monnier N, Lunardi J, Drouet C. Mutational		
486		spectrum and phenotypes in Danish families with hereditary angioedema because of C1		
487		inhibitor deficiency. Allergy 2011; 66:76-84.		
488	29.	Porebski G, Kwitniewski M, Reshef A. Biomarkers in Hereditary Angioedema. Clin Rev		
489		Allergy Immunol 2021; 60:404-15		
490	30.	Zuraw BL, Christiansen SC. HAE Pathophysiology and Underlying Mechanisms. Clin		
491		Rev Allergy Immunol 2016; 51:216-29.		
492	31.	Kaplan AP, Joseph K, Ghebrehiwet B. The complex role of kininogens in hereditary		
493		angioedema. Front Allergy 2022; 3:952753.		
494	32.	Bork K, Wulff K, Rossmann H, Steinmuller-Magin L, Braenne I, Witzke G, et al.		
495		Hereditary angioedema cosegregating with a novel kininogen 1 gene mutation changing		
496		the N-terminal cleavage site of bradykinin. Allergy 2019; 74:2479-81.		
497	33.	Morgan BP. Complement in the pathogenesis of Alzheimer's disease. Semin		
498		Immunopathol 2018; 40:113-24.		
499				
500	Figur	e Legends		
501	Figure 1. Urinary proteome profiling of type 1 HAE, type 2 HAE and HCs.			
502	(A) OPLS-DA of type 1 HAE, type 2 HAE, and heathy controls; (B) OPLS-DA of			
503	type 1	HAE and type 2 HAE; (C-D) PCA and OPLS-DA of type 1 HAE and HCs.		
504				
505	Figur	e 2. Bioinformatics analysis of DEPs between type 1 HAE patients and HCs.		
506	(A-B) Biological processes and molecular functions annotated in the DAVID database;			
507	(C-D)	canonical pathway and disease & biofunction annotation of DEPs in IPA.		
508				
509	Figure	e 3. Coexpression network analysis of potential biomarkers of HAE. (A)		
510	Ten hub proteins of the coexpression network; (B) the major functions of the hub			
511	proteii	IS.		
512				
513	Figur	e 4. Diagnostic performance and clinical association of candidate		
514	biomarkers. (A) The ROC analysis result of a biomarker panel (EGF+C1-INH+			
515	KNG1) in DIA; (B) correlation of the urinary CLU level and disease severity score of			
516	HAE.			
517				
518	Figure 5. Targeted validation of promising biomarkers in another cohort. (A-C)			
519	DIA a	DIA and PRM proteome quantification of C1IN, KNG1 and EGF in urine samples; (D)		
520	ROC analysis of the biomarker panel (C1IN+ KNG1+EGF) in PRM.			











Sensitivity



